Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients
- 1 August 2003
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 80 (3) , 245-255
- https://doi.org/10.1023/a:1024911625339
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogenOncogene, 2000
- Estrogen Receptor, c‐erbB‐2 and nm23/NDP Kinase Expression in the Intraductal and Invasive Components of Human Breast CancersJapanese Journal of Cancer Research, 1992
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3Journal of Biological Chemistry, 1991
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature, 1984